<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803188</url>
  </required_header>
  <id_info>
    <org_study_id>5996</org_study_id>
    <nct_id>NCT04803188</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Secondary Screening in Sapienza and Policlinico Umberto I</brief_title>
  <acronym>ProSa-I</acronym>
  <official_title>A Randomized Controlled Trial on the Role of Magnetic Resonance Imaging for Prostate Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate Cancer (PCa) screening is still a controversial topic in the urology community, this&#xD;
      is mostly linked to the low specificity of Prostate Specific Antigen (PSA) value. Screening&#xD;
      with total PSA value has cause overdiagnosis of clinically insignificant prostate cancer&#xD;
      (ciPCa) for many years, with lack of survival improvement. Non-contrast MRI, on the other&#xD;
      hand, has become one of the most promising MRI applications, as it is a more sensitive test&#xD;
      able to perform clinically significant PCa early detection. With this background the primary&#xD;
      endpoint was to investigate the role of non-contrast MRI (without injection of paramagnetic&#xD;
      contrast medium), as a secondary prevention test for the early diagnosis of prostate cancer,&#xD;
      comparing it with the serum PSA test, in a randomized fashion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ENDPOINTS Primary endpoint To investigate the role of non-contrast Magnetic Resonance Imaging&#xD;
      (MRI), as a secondary prevention test for the early diagnosis of prostate cancer (PCa),&#xD;
      comparing it with the serum PSA test.&#xD;
&#xD;
      Secondary endpoints&#xD;
&#xD;
        1. Assess the percentage of men with a positive PSA screening test, defined as &gt; 4 ng/ml&#xD;
           and &gt; 2.5 ng/ml in patients with family history of PCa (father and/or sibling).&#xD;
&#xD;
        2. Evaluation of the percentage of men with positive MRI and MRI targeted biopsy results&#xD;
           stratified according to: absence of neoplasm, non-clinically significant neoplasm (ISUP&#xD;
           1) and clinically significant neoplasm (ISUP&gt; 1), compared with PSA test and serum&#xD;
           biomarkers (optional).&#xD;
&#xD;
        3. Comparison of the percentages of participants with PCa and with clinically significant&#xD;
           PCa, according to the different positive screening tests.&#xD;
&#xD;
        4. Comparison of the different screening tests combinations in terms of PCa detection rate,&#xD;
           both for non-clinically significant and clinically significant cancer.&#xD;
&#xD;
      STUDY DESIGN&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Single center, prospective, interventional randomized controlled trial Duration: 2 years&#xD;
      Evaluation of the effectiveness of the primary outcome: the evaluation of the effectiveness&#xD;
      non-contrast MRI for the PCa detection will be based on MRI-guided biopsy targeted on the&#xD;
      areas described and classified as biparametric Prostate Imaging-Reporting and Data System&#xD;
      (bPI-RADS) ≥3 (scored according to the biparametric evaluation).&#xD;
&#xD;
      The reference standard for the diagnosis of prostate cancer will be the Magnetic Resonance&#xD;
      Imaging - Transrectal Ultrasound (MRI-TRUS) guided targeted biopsy, which will be performed&#xD;
      at a maximum of 4 weeks from MRI.&#xD;
&#xD;
      In order to evaluate the diagnostic accuracy of non-contrast MRI the diagnostic performance&#xD;
      variables (sensitivity, specificity, accuracy, positive and negative predictive value, area&#xD;
      under the curve and receiver operating characteristic curves) will be calculated.&#xD;
&#xD;
      For the statistical analysis of the effectiveness, only those participants who have undergone&#xD;
      prostate biopsy as planned by the operator will be included.&#xD;
&#xD;
      In addition, the interreader agreement between two radiologists responsible for the analysis&#xD;
      of MRI images, with 10 and 8 years of experience in urogenital imaging, respectively, will be&#xD;
      evaluated. The agreement between the two radiologists will be calculated using the weighted&#xD;
      Cohen's k statistic.&#xD;
&#xD;
      Evaluation of secondary outcomes: the evaluation of the effectiveness of secondary outcomes&#xD;
      will be verified by evaluating the same statistical variables of diagnostic accuracy&#xD;
      implemented for the primary purpose.&#xD;
&#xD;
      Safety evaluation: the safety of the procedure will be determined by assessing the incidence&#xD;
      and severity of adverse events, defined as complications related to the procedure recorded&#xD;
      from the first treatment and during the entire duration of the follow-up (2 years).&#xD;
&#xD;
      Participants in the study:&#xD;
&#xD;
      Enrollment: 710 men will be enrolled and blindly randomized in two different arms. Arm a) 355&#xD;
      patients will perform MRI with a bi-parametric approach (without contrast medium) regardless&#xD;
      their PSA value; Arm b) 355 patients will perform MRI with a bi-parametric approach (without&#xD;
      contrast medium) only when PSA is elevated.&#xD;
&#xD;
      Patients with positive MRI defined as bPI-RADS ≥3, will undergo MRI-directed targeted&#xD;
      prostate biopsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of prostate cancer with non-contrast MRI</measure>
    <time_frame>24 months</time_frame>
    <description>To investigate the role of MRI with a bi-parametric approach (without injection of paramagnetic contrast medium), as a secondary prevention test for the early diagnosis of prostate cancer, comparing it with the serum PSA test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of men with a positive PSA screening test</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the percentage of men with a positive PSA screening test, defined as &gt; 4 ng/ml and &gt; 2.5 ng/ml in patients with family history of prostate cancer (father and/or sibling).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stratification according to outcome</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the percentage of men with positive non-contrast MRI stratified according to: absence of neoplasm, non-clinically significant neoplasm (ISUP 1) and clinically significant neoplasm (ISUP&gt; 1), compared with the tests of the PSA and serum biomarkers (optional).</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of different positive screening tests</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of the percentages of participants with the different positive screening tests. Comparison of the same in the subpopulation of patients with clinically significant neoplasia (ISUP&gt; 1).</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of different combination of screening tests</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of the different combination of screening tests in terms of detection rate, non-clinically significant and clinically significant cancer detection rate.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">710</enrollment>
  <condition>Prostate Cancer (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>A: patients will perform non-contrast MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: 355 patients will perform non-contrast MRI regardless their serum PSA value</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: patients will perform non-contrast MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B: 355 patients will perform non-contrast MRI when serum PSA value is increased (&gt;4 ng/ml or 2.5 ng/ml if positive family history)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance</intervention_name>
    <description>Screening MRI examinations will be performed on an MRI General Electric (GE) 3 Tesla MRI using a 32-channel phased array pelvic coil. The imaging protocol will include: T2-weighted morphological and diffusion-weighted functional sequences.&#xD;
All images will be reviewed by two radiologists experienced in urogenital imaging, who will be blinded to the patients' medical history. Both radiologists in charge will then assign a PI-RADS score (1 to 5) to each lesion for bi-parametric MRI, representing the likelihood of a clinically significant prostate lesion. For the generation of the overall PI-RADS score assigned to each lesion, the PI-RADS score algorithm for non-contrast MRI described in the PI-RADS version 2.1 recommendations will be applied. Lesions scored as bPI-RADS superior or equal than 3 will be directed to MRI-TRUS guided targeted biopsy.</description>
    <arm_group_label>A: patients will perform non-contrast MRI</arm_group_label>
    <arm_group_label>B: patients will perform non-contrast MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Males aged between 49-69 years (from the age of 40 for those with family history of&#xD;
             prostate cancer) at the time of enrollment&#xD;
&#xD;
          -  Life expectancy greater than or equal to 10 years&#xD;
&#xD;
          -  Sufficient understanding of the Italian language for written and verbal understanding&#xD;
             of the information for enrollment in the Trial and for the process of obtaining&#xD;
             informed consent.&#xD;
&#xD;
          -  Patient with the ability to understand and want, able to express informed consent and&#xD;
             to perform all the visits and procedures required by the study&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  General contraindications to MRI&#xD;
&#xD;
          -  Previous history of prostate cancer, prostate biopsy or treatment for prostate cancer&#xD;
&#xD;
          -  Any contraindications to prostate biopsy, such as severe coagulation abnormalities&#xD;
             (INR&gt; 1.5), active urinary tract infection and acute prostatitis (NIH category I, II&#xD;
             and III).&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit understanding or granting&#xD;
             informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valeria Panebianco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapienza University of Rome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sapienza University of Rome</name>
      <address>
        <city>Rome</city>
        <state>Roma</state>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530. Review.</citation>
    <PMID>26492179</PMID>
  </results_reference>
  <results_reference>
    <citation>Matoso A, Epstein JI. Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology. 2019 Jan;74(1):135-145. doi: 10.1111/his.13712. Review.</citation>
    <PMID>30565298</PMID>
  </results_reference>
  <results_reference>
    <citation>Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7.</citation>
    <PMID>33172724</PMID>
  </results_reference>
  <results_reference>
    <citation>Welch HG, Albertsen PC. Reconsidering Prostate Cancer Mortality - The Future of PSA Screening. N Engl J Med. 2020 Apr 16;382(16):1557-1563. doi: 10.1056/NEJMms1914228.</citation>
    <PMID>32294352</PMID>
  </results_reference>
  <results_reference>
    <citation>Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, Bosch JLHR, Barentsz JO, Somford DM, van Melick HHE. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. 2019 Apr;75(4):582-590. doi: 10.1016/j.eururo.2018.11.040. Epub 2018 Dec 3.</citation>
    <PMID>30522912</PMID>
  </results_reference>
  <results_reference>
    <citation>Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019 Sep;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033. Epub 2019 Mar 18. Review.</citation>
    <PMID>30898406</PMID>
  </results_reference>
  <results_reference>
    <citation>Nam RK, Wallis CJ, Stojcic-Bendavid J, Milot L, Sherman C, Sugar L, Haider MA. A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population. J Urol. 2016 Aug;196(2):361-6. doi: 10.1016/j.juro.2016.01.114. Epub 2016 Feb 13.</citation>
    <PMID>26880413</PMID>
  </results_reference>
  <results_reference>
    <citation>Boesen L, Nørgaard N, Løgager V, Balslev I, Bisbjerg R, Thestrup KC, Winther MD, Jakobsen H, Thomsen HS. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Netw Open. 2018 Jun 1;1(2):e180219. doi: 10.1001/jamanetworkopen.2018.0219.</citation>
    <PMID>30646066</PMID>
  </results_reference>
  <results_reference>
    <citation>Jambor I, Boström PJ, Taimen P, Syvänen K, Kähkönen E, Kallajoki M, Perez IM, Kauko T, Matomäki J, Ettala O, Merisaari H, Kiviniemi A, Dean PB, Aronen HJ. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). J Magn Reson Imaging. 2017 Oct;46(4):1089-1095. doi: 10.1002/jmri.25641. Epub 2017 Feb 6.</citation>
    <PMID>28165653</PMID>
  </results_reference>
  <results_reference>
    <citation>Knaapila J, Jambor I, Ettala O, Taimen P, Verho J, Perez IM, Kiviniemi A, Pahikkala T, Merisaari H, Lamminen T, Saunavaara J, Aronen HJ, Syvänen KT, Boström PJ. Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies. Eur Urol Focus. 2021 May;7(3):522-531. doi: 10.1016/j.euf.2020.04.007. Epub 2020 May 14.</citation>
    <PMID>32418878</PMID>
  </results_reference>
  <results_reference>
    <citation>Eldred-Evans D, Burak P, Connor MJ, Day E, Evans M, Fiorentino F, Gammon M, Hosking-Jervis F, Klimowska-Nassar N, McGuire W, Padhani AR, Prevost AT, Price D, Sokhi H, Tam H, Winkler M, Ahmed HU. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study. JAMA Oncol. 2021 Mar 1;7(3):395-402. doi: 10.1001/jamaoncol.2020.7456.</citation>
    <PMID>33570542</PMID>
  </results_reference>
  <results_reference>
    <citation>Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, Campa R, Indino EL, Barchetti F, Sciarra A, Leonardo C, Gallucci M, Catalano C. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next? Eur Urol. 2018 Jul;74(1):48-54. doi: 10.1016/j.eururo.2018.03.007. Epub 2018 Mar 19.</citation>
    <PMID>29566957</PMID>
  </results_reference>
  <results_reference>
    <citation>Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.</citation>
    <PMID>29552975</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Valeria Panebianco</investigator_full_name>
    <investigator_title>Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Screening</keyword>
  <keyword>Non-contrast MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all individual participant data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Starting in January 2022, will be available for 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>The access will be granted to any researcher who will contact the principal investigator via email, upon reasonable request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

